Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Operating Income: 2009-2024

Historic Operating Income for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Dec 2024 value amounting to -$40.7 million.

  • Vanda Pharmaceuticals' Operating Income fell 184.40% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$121.1 million, marking a year-over-year decrease of 223.13%. This contributed to the annual value of -$40.7 million for FY2024, which is 191.43% down from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Operating Income stood at -$40.7 million for FY2024, which was down 191.43% from -$14.0 million recorded in FY2023.
  • In the past 5 years, Vanda Pharmaceuticals' Operating Income ranged from a high of $42.2 million in FY2021 and a low of -$40.7 million during FY2024.
  • Moreover, its 3-year median value for Operating Income was -$14.0 million (2023), whereas its average is -$16.1 million.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Operating Income skyrocketed by 54.80% in 2021 and then crashed by 320.45% in 2023.
  • Yearly analysis of 5 years shows Vanda Pharmaceuticals' Operating Income stood at $27.2 million in 2020, then soared by 54.80% to $42.2 million in 2021, then tumbled by 84.99% to $6.3 million in 2022, then slumped by 320.45% to -$14.0 million in 2023, then tumbled by 191.43% to -$40.7 million in 2024.